Clinical Trial Update: The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan [NA]

View source ↗

Summary

A terminated clinical trial evaluated whether sevelamer carbonate (Renvela) reduces atherosclerotic plaque inflammation in dialysis patients with Hyperphosphate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Cardiovascular Disease
• Chronic Kidney Disease
• End-stage Renal Disease
• Hyperphosphatemia

Drugs mentioned

• Renvela (sevelamer carbonate)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Dialysis, Cardiovascular Disease | NA | Status: TERMINATED | Results posted: 2017-06-21